Literature DB >> 20627427

Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan.

Dennis McCarty1, Nancy A Perrin, Carla A Green, Michael R Polen, Michael C Leo, Frances Lynch.   

Abstract

BACKGROUND: Few health plans provide maintenance medication for opioid dependence. This study assessed the cost of treating opioid-dependent members in a commercial health plan and the impacts of methadone maintenance on costs of care.
METHODS: Individuals with diagnoses of opioid dependence (two or more diagnoses per year) and at least 9 months of health plan eligibility each year were extracted from electronic health records for the years 2000 through 2004 (1,518 individuals and 2,523 observations across the study period-some individuals were in multiple years). Analyses examined the patterns and costs of health care for three groups of patients: (1) one or more methadone visits during the year (n=1,298; 51%); (2) no methadone visits and 0 or 1 visits in the Addiction Medicine Department (n=370; 15%); (3) no methadone visits and 2 or more visits in addiction medicine (n=855; 34%).
RESULTS: Primary care (86%), emergency department (48%) and inpatient (24%) visits were common. Mean total annual costs to the health plan were $11,200 (2004 dollars) per member per year. The health plan's costs for members receiving methadone maintenance were 50% lower ($7,163) when compared to those with two or more outpatient addiction treatment visits but no methadone ($14,157) and 62% lower than those with one or zero outpatient addiction treatment visits and no methadone treatment ($18,694).
CONCLUSIONS: Use of opioid maintenance services was associated with lower total costs of care for opioid-dependent members in a commercial health plan.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20627427      PMCID: PMC2950212          DOI: 10.1016/j.drugalcdep.2010.04.018

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  17 in total

1.  Measures of clinical significance.

Authors:  Helena Chmura Kraemer; George A Morgan; Nancy L Leech; Jeffrey A Gliner; Jerry J Vaske; Robert J Harmon
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-12       Impact factor: 8.829

2.  A disease classification system for analysis of medical care utilization, with a note on symptom classification.

Authors:  A V Hurtado; M R Greenlick
Journal:  Health Serv Res       Date:  1971       Impact factor: 3.402

3.  Methadone maintenance and state Medicaid managed care programs.

Authors:  D McCarty; R G Frank; G C Denmead
Journal:  Milbank Q       Date:  1999       Impact factor: 4.911

4.  Medical service use and financial charges among opioid users at a public hospital.

Authors:  Carmen L Masson; James L Sorensen; Steven L Batki; Robert Okin; Kevin L Delucchi; David C Perlman
Journal:  Drug Alcohol Depend       Date:  2002-03-01       Impact factor: 4.492

Review 5.  The cost-effectiveness of methadone maintenance as a health care intervention.

Authors:  P G Barnett
Journal:  Addiction       Date:  1999-04       Impact factor: 6.526

6.  Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs.

Authors:  C Laine; W W Hauck; M N Gourevitch; J Rothman; A Cohen; B J Turner
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

7.  Injection frequency mediates health service use among persons with a history of drug injection.

Authors:  Michael D Stein; Bradley Anderson
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

Review 8.  Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction.

Authors: 
Journal:  JAMA       Date:  1998-12-09       Impact factor: 56.272

Review 9.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

10.  Buprenorphine versus methadone maintenance: a cost-effectiveness analysis.

Authors:  Christopher M Doran; Marian Shanahan; Richard P Mattick; Robert Ali; Jason White; James Bell
Journal:  Drug Alcohol Depend       Date:  2003-09-10       Impact factor: 4.492

View more
  19 in total

1.  Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement.

Authors:  Scott P Stumbo; Bobbi Jo H Yarborough; Dennis McCarty; Constance Weisner; Carla A Green
Journal:  J Subst Abuse Treat       Date:  2016-11-15

2.  Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings.

Authors:  Robert P Schwartz; Sharon M Kelly; Kevin E O'Grady; Devang Gandhi; Jerome H Jaffe
Journal:  Addiction       Date:  2012-02-11       Impact factor: 6.526

Review 3.  Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.

Authors:  Elizabeth M Oliva; Natalya C Maisel; Adam J Gordon; Alex H S Harris
Journal:  Curr Psychiatry Rep       Date:  2011-10       Impact factor: 5.285

4.  Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.

Authors:  Heide Jackson; Kara Mandell; Kimberly Johnson; Debanjana Chatterjee; David J Vanness
Journal:  Subst Abus       Date:  2015-03-16       Impact factor: 3.716

5.  Sex Differences in Regional Brain Glucose Metabolism Following Opioid Withdrawal and Replacement.

Authors:  Giovanni C Santoro; Joseph Carrion; Krishna Patel; Crystal Vilchez; Jennifer Veith; Jonathan D Brodie; Stephen L Dewey
Journal:  Neuropsychopharmacology       Date:  2017-04-10       Impact factor: 7.853

6.  Trends in Abstinence and Retention Associated with a Medication-Assisted Treatment Program for People with Opioid Use Disorders.

Authors:  Kimberly D Brunisholz; Andrew J Knighton; Amulya Sharma; Lisa Nichols; Kristen Reisig; Jed Burton; Debbie Scovill; Carolyn Tometich; Mark Foote; Shelly Read; Scott Whittle
Journal:  Prog Community Health Partnersh       Date:  2020

7.  Contingency management is efficacious in opioid-dependent outpatients not maintained on agonist pharmacotherapy.

Authors:  Nancy M Petry; Kathleen M Carroll
Journal:  Psychol Addict Behav       Date:  2013-03-25

8.  Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.

Authors:  Bobbi Jo H Yarborough; Scott P Stumbo; Dennis McCarty; Jennifer Mertens; Constance Weisner; Carla A Green
Journal:  Drug Alcohol Depend       Date:  2016-01-06       Impact factor: 4.492

Review 9.  Economic Evaluations of Opioid Use Disorder Interventions.

Authors:  Sean M Murphy; Daniel Polsky
Journal:  Pharmacoeconomics       Date:  2016-09       Impact factor: 4.981

10.  Promoting Adoption of Medication for Opioid and Alcohol Use Disorders Through System Change.

Authors:  James H Ford; Amanda J Abraham; Nicoleta Lupulescu-Mann; Raina Croff; Kim A Hoffman; Kelly Alanis-Hirsch; Mady Chalk; Laura Schmidt; Dennis McCarty
Journal:  J Stud Alcohol Drugs       Date:  2017-09       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.